RARA and glioblastoma: Based on the R package “pRRophetic”, we predicted drugs in glioblastoma patients and found that compared with the RARA-AS1 low-expression group, drugs such as KIN001-055, GSK-650394, Shikonin, and QS11 had lower IC50 values in the RARA-AS1 high-expression group, indicating that a relatively lower drug concentration can achieve better therapeutic effects in the RARA-AS1 high-expression group (Fig. 8A,B).